Skip to main content

Table 5 Multivariable-adjusted hazard ratios for the association between body fatness and ER/PR-defined subtypes of postmenopausal breast cancer by MHT use

From: Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer

 

Ever MHT usea

Never MHT usea

ER + /PR + (n = 1956)

ER-/PR- (n = 342)

phetc

ER + /PR + (n = 2230)

ER-/PR- (n = 447)

phetc

Cases

MV-adjusted HR (95% CI)b

Cases

MV-adjusted HR (95% CI)b

 

Cases

MV-adjusted HR (95% CI)b

Cases

MV-adjusted HR (95% CI)b

 

Age at onset (yrs)d

BMI ≥ 25

Never OW

1046

Ref

182

Ref

 

1151

Ref

261

Ref

 

< 40

283

0.95 (0.83–1.08)

47

0.89 (0.64–1.23)

 

469

1.22 (1.09–1.36)

89

1.03 (0.80–1.31)

 

40–49

392

1.13 (1.00–1.27)

68

1.11 (0.84–1.47)

 

455

1.37 (1.22–1.52)

67

0.90 (0.69–1.19)

 

≥ 50

235

1.04 (0.90–1.20)

45

1.18 (0.85–1.64)

 

155

1.10 (0.93–1.31)

30

1.00 (0.68–1.48)

 

ptrende

 

0.21

 

0.26

 0.85

 

 < 0.01

 

0.74

 0.04

BMI ≥ 30

Never OB

1775

Ref

312

Ref

 

1946

Ref

403

Ref

 

< 40

22

0.73 (0.48–1.11)

3

0.56 (0.18–1.74)

 

56

1.00 (0.77–1.31)

9

0.77 (0.40–1.50)

 

40–49

66

0.92 (0.72–1.17)

15

1.13 (0.67–1.91)

 

115

1.26 (1.04–1.52)

21

1.12 (0.72–1.75)

 

 ≥ 50

93

1.02 (0.83–1.26)

12

0.76 (0.43–1.36)

 

113

1.56 (1.29–1.89)

14

0.99 (0.58–1.70)

 

ptrende

 

0.81

 

0.45

 0.64

 

 < 0.01

 

0.92

 0.35

Duration (per 10 yrs)d

BMI ≥ 25

910

1.00 (0.96–1.04)

160

0.98 (0.88–1.09)

0.92

1,079

1.09 (1.05–1.13)

186

0.98 (0.89–1.08)

0.04

BMI ≥ 30

181

0.96 (0.85–1.08)

30

0.91 (0.67–1.23)

0.83

284

1.06 (0.97–1.17)

44

0.97 (0.77–1.24)

0.47

Intensity (per 100 units)d

OWY

910

0.95 (0.85–1.06)

160

0.93 (0.71–1.22)

0.99

1,079

1.10 (1.01–1.20)

186

0.95 (0.76–1.19)

0.21

OBY

181

0.88 (0.62–1.24)

30

1.05 (0.50–2.17)

0.63

284

0.98 (0.76–1.26)

44

0.89 (0.48–1.68)

0.77

Trajectoriesf, g

Normal-stable

874

Ref

157

Ref

 

864

Ref

207

Ref

 

Normal-overweight

822

1.04 (0.94–1.14)

146

1.02 (0.81–1.28)

0.92

943

1.14 (1.04–1.26)

169

0.86 (0.70–1.05)

0.01

Normal-obesity

222

1.02 (0.88–1.18)

33

0.82 (0.56–1.20)

 0.33

349

1.34 (1.18–1.52)

57

0.91 (0.67–1.22)

 0.01

Overweight-obesity

26

0.77 (0.52–1.14)

5

0.79 (0.32–1.93)

0.93

67

1.20 (0.93–1.54)

11

0.81 (0.44–1.49)

0.23

Obesity-decrease

12

0.78 (0.44–1.37)

1

0.39 (0.05–2.76)

0.44

7

0.41 (0.20–0.87)

3

0.79 (0.25–2.47)

0.39

ptrende

 

 0.64

 

 0.26

  

  <0.01

 

 0.23

 
  1. CI confidence interval, HR hazard ratio, ER estrogen receptor, MHT menopausal hormone therapy, MV multivariable, OBY weighted cumulative obesity years, OWY weighted cumulative overweight years, p p-value
  2. aBased on last reported MHT status prior to censoring
  3. bAdjusted for age, age at menarche, parity, age at first birth, breast cancer in mother, smoking, physical activity
  4. cp heterogeneity between ER + /PR + and ER−/PR− subtype; likelihood ratio test by competing risks analysis
  5. dBased on linear mixed effects models. Never overweight/obesity as reference group
  6. ep trend, continuous variable
  7. fBased on group-based trajectory modeling
  8. gNormal weight: 18.5–24.9 kg/m2; overweight: 25–29–9 kg/m2; obesity: ≥ 30 kg/m2
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us